{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:50:18Z","timestamp":1761897018715,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clml.2019.05.020","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T22:22:40Z","timestamp":1559686960000},"page":"585-592.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5506-0244","authenticated-orcid":false,"given":"Susanna","family":"Gassiot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Morgades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Motll\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vict\u00f2ria","family":"Clap\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Maluquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladys","family":"Ibarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Abril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep-Maria","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.05.020_bib1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.020_bib2","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.05.020_bib3","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.05.020_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.05.020_bib5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.05.020_bib6","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.05.020_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.05.020_bib8","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.05.020_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.critrevonc.2017.11.016","article-title":"A\u00a0question of class: treatment options for patients with relapsed and\/or refractory multiple myeloma","volume":"121","author":"Cook","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2019.05.020_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3816\/CLML.2010.n.120","article-title":"Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","volume":"11","author":"San-Miguel","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.05.020_bib11","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3324\/haematol.2009.015917","article-title":"Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma","volume":"95","author":"Harousseau","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.05.020_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.91","article-title":"Characteristics of exceptional responders to lenalidomide based therapy in multiple myeloma","volume":"5","author":"Vu","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.05.020_bib13","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.05.020_bib14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.05.020_bib15","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.020_bib16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood-2015-05-647636","article-title":"Guidelines for determination of the number of prior lines of therapy in multiple myeloma","volume":"126","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"15 suppl","key":"10.1016\/j.clml.2019.05.020_bib17","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2017.35.15_suppl.8000","article-title":"Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study","volume":"35","author":"Jakubowiak","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.020_bib18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.020_bib19","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.05.020_bib20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V128.22.1150.1150","article-title":"Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of castor","volume":"128","author":"Mateos","year":"2016","journal-title":"Blood"},{"year":"2018","series-title":"OPTIMISMM: phase 3 trial of pomalidomide, bortezomib, and low-dose dexamethasone vs. bortezomib and low-dose dexamethasone in lenalidomide-exposed patients with relapsed\/refractory multiple myeloma [abstract S847]","author":"Richardson","key":"10.1016\/j.clml.2019.05.020_bib21"},{"key":"10.1016\/j.clml.2019.05.020_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clml.2016.11.010","article-title":"Practical considerations in managing relapsed multiple myeloma","volume":"17","author":"Agarwal","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.05.020_bib23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","article-title":"The Role of Diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma","volume":"1","author":"Sigurdardottir","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2019.05.020_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2019.05.020_bib25","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","article-title":"From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells","volume":"78","author":"van Nieuwenhuijzen","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2019.05.020_bib26","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS ) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.020_bib27","doi-asserted-by":"crossref","first-page":"246LP","DOI":"10.1182\/blood.V128.22.246.246","article-title":"Evaluation of minimal residual disease (MRD) in relapsed\/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2019.05.020_bib28","first-page":"1883","article-title":"Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM) based on prior treatment history, renal function, and cytogenetic risk: subgroup analyses of Pollux","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.020_bib29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.05.020_bib30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2009.01257.x","article-title":"Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma","volume":"82","author":"Stadtmauer","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.05.020_bib31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/leu.2009.273","article-title":"Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexam\u00e9thasone","volume":"24","author":"Avet-Loiseau","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.05.020_bib32","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.020_bib33","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.clml.2017.02.018","article-title":"High-risk multiple myeloma: definition and management","volume":"17","author":"Joseph","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.05.020_bib34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bmt.2015.307","article-title":"Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: Increased options and increased complexity","volume":"51","author":"Cornell","year":"2016","journal-title":"Bone Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018316124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018316124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:26Z","timestamp":1761870806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018316124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2152265018316124"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.020","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}